ArticleClinical kidney journal2026
Dietary sodium reduction and blood pressure: a dose-response meta-analysis in hypertensive and chronic kidney disease patients.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Efficacy and safety of potassium-containing low-sodium salt substitutes for cardiovascular disease prevention in mixed adult populations: an umbrella review.medRxiv : the preprint server for health sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypertension (HTN) is a leading risk factor for cardiovascular disease, and dietary sodium reduction is a cornerstone strategy for blood pressure (BP) control, particularly in vulnerable populations such as individuals with chronic kidney disease (CKD), who often present with HTN. This study aims to quantify the dose-response relationship between changes in sodium intake and changes in BP, through a meta-analysis of recent randomized controlled trials (RCTs) in individuals with CKD and with or without HTN. Methods: A systematic literature search was conducted in PubMed, Cochrane Central and Embase databases to identify RCTs published since 2000 that evaluated the isolated effect of sodium intake modification on systolic and diastolic. Only trials estimating sodium intake via 24-h urinary sodium excretion were included to ensure accurate measurement of dietary intervention. A random-effects model was used to pool effect sizes, accounting for between-study heterogeneity. Linear, quadratic and cubic dose-response models were fitted and compared with identify the best-fitting relationship between sodium change and BP change. Results: The analysis included 43 RCTs with 51 distinct population groups, involving 1759 subjects. The linear model best described the dose-response relationship in subjects with CKD, with or without HTN. A reduction in sodium intake of 40 mmol/day (approximately 2.4 g of salt) was associated with a mean systolic BP/diastolic BP reduction of -4.5 mmHg (95% confidence interval -5.8, -3.1)/-2.2 mmHg (-3.0, -1.3) in patients with CKD, -2.3 mmHg (-3.0, -1.6)/-1.1 mmHg (-1.5, -0.6) in patients with HTN and -0.3 mmHg (-0.5, -0.1)/-0.1 mmHg (-0.2, -0.1) in patients without HTN. Conclusion: Reducing sodium intake has a pronounced antihypertensive effect in patients with CKD and/or HTN. Regardless of the variability in effect according to BP status, adopting a low-salt diet represents good clinical practice and should be considered a standard prescription, particularly for individuals with CKD, as it supports better BP control and helps reduce cardiovascular risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.